| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Dexrazoxane monoHCl (formerly also known as ICRF-187, ADR-529) acts as an intracellular iron chelator, which decreases the formation of superoxide radicals, and is mainly used as a cardioprotective agent. As a derivative of EDTA, dexrazoxane chelates iron, but the precise mechanism by which it protects the heart is not known. This agent is used to protect the heart against the cardiotoxic side effects. Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes.
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Dextrazosen is hydrolyzed in the liver and kidneys by dihydropyrimidine amide hydrolases into its active metabolites, which can bind to metal ions. Excretion pathway: Urinary excretion plays a crucial role in the clearance of dextrazosen. 42% of a 500 mg/m² dose of dextrazosen is excreted in the urine. Half-life: 2.5 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the use of dexrazoxane during lactation. The manufacturer recommends that women refrain from breastfeeding during treatment and for two weeks after the last dose of dexrazoxane. However, because dexrazoxane is used in combination with doxorubicin, the abstinence period may be longer depending on the doxorubicin dosage. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. |
| References |
Circ Res.1999 Feb 19;84(3):257-65;Cancer Res.2007 Sep 15;67(18):8839-46. |
| Additional Infomation |
Dexrazoxane hydrochloride is the hydrochloride salt of dioxanepiperazine, possessing iron-chelating, chemoprotective, cardioprotective, and antitumor activities. Upon hydrolysis, dexrazoxane is converted to an active form similar to ethylenediaminetetraacetic acid (EDTA), chelating iron and thus limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to the heart and soft tissues. The drug also inhibits the catalytic activity of topoisomerase II, thereby inhibiting tumor cell growth.
(+)-enantiomers of dexrazoxane. See also: Dexrazoxane (with active moiety). Drug Indications Savene is indicated for the treatment of anthracycline extravasation. |
| Molecular Formula |
C11H17CLN4O4
|
|---|---|
| Molecular Weight |
304.730081319809
|
| Exact Mass |
304.093
|
| CAS # |
1263283-43-7
|
| Related CAS # |
24584-09-6;1263283-43-7 (HCl);
|
| PubChem CID |
6918223
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
404
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl
|
| InChi Key |
BIFMNMPSIYHKDN-FJXQXJEOSA-N
|
| InChi Code |
InChI=1S/C11H16N4O4.ClH/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14;/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19);1H/t7-;/m0./s1
|
| Chemical Name |
4-[(2S)-2-(3,5-Dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride
|
| Synonyms |
Cardioxane Zinecard Totect Dexrazoxane HCl Dexrazoxane Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2816 mL | 16.4080 mL | 32.8159 mL | |
| 5 mM | 0.6563 mL | 3.2816 mL | 6.5632 mL | |
| 10 mM | 0.3282 mL | 1.6408 mL | 3.2816 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04293562
Conditions:Acute Myeloid LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT03007147
Conditions:Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT03126916
Conditions:Ganglioneuroblastoma|Ganglioneuroblastoma, Nodular|Neuroblastoma
Title:05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Status:Completed
updateDate:2026-02-13
Ctid:NCT00400946
Link: https://clinicaltrials.gov/ct2/show/NCT00400946
Conditions:Drug/Agent Toxicity by Tissue/Organ|LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT03589729
Conditions:Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Myeloid Sarcoma|Myeloproliferative Neoplasm|Philadelphia Chromosome PositiveLink: https://clinicaltrials.gov/ct2/show/NCT00077285
Conditions:SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT01606878
Conditions:Childhood Solid Neoplasm|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent NeuroblastomaLink: https://clinicaltrials.gov/ct2/show/NCT00098839
Conditions:Recurrent Childhood Acute Lymphoblastic LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT00084838
Conditions:Central Nervous System Tumor, PediatricLink: https://clinicaltrials.gov/ct2/show/NCT00019864
Conditions:Cardiac Toxicity|SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT00550901
Conditions:Unspecified Adult Solid Tumor, Protocol SpecificLink: https://clinicaltrials.gov/ct2/show/NCT00544778
Conditions:SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT00003937
Conditions:Cardiac Toxicity|SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT00005578
Conditions:Cardiac Toxicity|LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00742924
Conditions:SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT00933985
Conditions:Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol SpecificLink: https://clinicaltrials.gov/ct2/show/NCT00002827
Conditions:Cardiac Toxicity|LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00334867
Conditions:SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT00003667
Conditions:SarcomaLink: https://clinicaltrials.gov/ct2/show/NCT01230983
Conditions:Cardiac Toxicity|Leukemia|LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00410488
Conditions:Sarcoma|Nausea|VomitingLink: https://clinicaltrials.gov/ct2/show/NCT00039481
Conditions:Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol SpecificLink: https://clinicaltrials.gov/ct2/show/NCT00016276
Conditions:Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast CancerLink: https://clinicaltrials.gov/ct2/show/NCT00955890
Conditions:Breast CancerProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
